HOME >> MEDICINE >> NEWS
Retinoblastoma researchers find success with two-drug combination

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

Retinoblastoma is a tumor that arises in the cells of the retina, the light-sensitive tissue at the back of the eyeball, following mutation of the gene RB1. It is the third most common form of cancer in infants. Left untreated, the cancer spreads and is fatal. Retinoblastoma strikes about 250-350 infants and young children each year in the United States.

The St. Jude study suggests a new approach to treatment that could save both lives and vision, according to Michael A. Dyer, PhD, an assistant member of the department of Developmental Neurobiology. The new treatment might also prevent recurrence of retinoblastoma in children whose cancer is very advanced, he noted. Dyer is the senior author of the Clinical Cancer Care report.

The study showed that combination therapy with topotecan and carboplatin is superior to the standard triple-drug therapy using vincristine, carboplatin and etoposide. The new combination eliminates the use of etoposide, which is known to increase the risk of the children getting a form of leukemia called acute myeloblastic leukemia. The findings also suggest that vincristine, which is used in the standard combination therapy, contributes little to the treatment of retinoblastoma, and therefore can be eliminated from therapy.

Dyer's group was prompted to look for new treatments because of the difficulty in managing this cancer. Patients with retinoblastoma usually undergo enucleation (removal of the diseased eye); and children with retinoblastoma in both eyes often must undergo anticancer therapy in order to avoid the loss of both eyes and blindness.

But despi
'"/>

Contact: Kelly Perry
kelly.perry@stjude.org
901-495-3306
St. Jude Children's Research Hospital
17-Oct-2005


Page: 1 2 3

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
(Date:11/26/2014)... Peoria, Il (PRWEB) November 27, 2014 ... is excited to announce the kick-off of its ... AlignLife encourages people to go to donate to ... will partner with local organizations to distribute the ... December 20th, participating AlignLife locations will be accepting ...
(Date:11/26/2014)... 2014 Recently, Locks-Magnetic.com, a Chinese outstanding ... of magnetic locks on the Internet. It also provides ... December. , As a leading company in the ... worldwide customers to buy high quality locks. It can ... provides locks that are not only useful but also ...
(Date:11/26/2014)... 2014 Pharmaceutical and biotech companies ... levels during manufacturing and research activities, a task ... systems play a key role. Changes in temperature ... while humidity can affect the quality of drugs ... HVAC systems helps to address these problems and ...
(Date:11/26/2014)... Alex Kramer HealthDay Reporter ... rheumatoid arthritis may be more likely to achieve remission if ... The study found that those who were heaviest had ... also lowered the odds of remission. "Medication for rheumatoid ... Dr. Susan Goodman, the study,s lead author and a rheumatologist ...
(Date:11/26/2014)... News) -- Even after they,re cleared to play following ... normal, which suggests they may not be fully recovered, ... a concussion may be symptom-free and cleared by MLB ... residual effects of concussion on the complex motor skills ... principal investigator Dr. Jeffrey Bazarian, an associate professor of ...
Breaking Medicine News(10 mins):Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3Health News:Harm From Baseball Concussions May Linger, Study Finds 2
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: